GLP-1.3

Product Details: GLP-1 Liraglutide Peptide

GLP-1 Liraglutide is a fatty-acid-modified analog of the endogenous glucagon-like peptide-1 (GLP-1). The peptide is chemically synthesized to ensure high purity and consistent structure. The fatty-acid modification increases stability, enabling prolonged receptor binding and intracellular signaling studies in vitro. [1]

This makes liraglutide suitable for controlled research on GLP-1 receptor interactions and associated signaling pathways.

Mechanism of Action

Liraglutide binds GLP-1 receptors with enhanced stability due to its fatty-acid modification. This allows detailed analysis of receptor-mediated intracellular signaling, including the following:

• cAMP accumulation. [2]
• Protein kinase A (PKA) activation. [3]
• Downstream effects on transcription factors such as CREB [4].

The peptide’s structural stability supports prolonged in vitro experiments without significant loss of activity, facilitating studies of receptor kinetics, ligand-binding efficiency, and intracellular signaling dynamics.

Properties of GLP-1 Liraglutide Peptide: 

• Molecular Formula: C₁₇₂H₂₆₅N₄₃O₅₁
• Molecular Weight: 3751 g/mol
• CAS Number: 204656-20-2 
• PubChem CID: 16134956 
• Synonyms: Liraglutide; NN2211; 

Research Applications/Benefits of GLP-1 Liraglutide Peptide

• GLP-1 Receptor Signaling: Supports investigation of cAMP-mediated and kinase-mediated pathways in cell models. [5]
• Peptide Stability Studies: Fatty-acid modification allows extended in vitro observation without rapid enzymatic degradation. [6]
• Ligand-Receptor Interaction Analysis: Facilitates evaluation of receptor kinetics, binding efficiency, and signaling dynamics in controlled experiments. [7]
• Second-Messenger Modulation: Enables precise measurement of intracellular signaling events, including kinase activation and transcription factor phosphorylation. [8]

Why Choose BehemothLabz for GLP-1 Liraglutide Peptide?

Choose BehemothLabz, choose quality! We are among the few online sellers that believe in the integrity and purity of products. Our GLP-1 Liraglutide Peptide is designed to meet the industrial criteria and the needs of researchers. Before launching our products, we test them through an independent laboratory to check their purity and ingredients. This procedure maximizes the accuracy and findings of your research experiments.  

Additionally, we deliver nationwide and internationally. We use a secure payment system that safeguards your personal information and prevents unauthorized third-party access.

So, purchase GLP-1 Liraglutide Peptide now and experience quality and purity for your research.

Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments. 

References: 

1. Han, J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H., & Huang, W. (2014). Novel coumarin modified GLP‐1 derivatives with enhanced plasma stability and prolonged in vivo glucose‐lowering ability. British Journal of Pharmacology, 171(23), 5252–5264. 
2. Feng, Y., Wang, L., Ma, X., Yang, X., Don, O., Chen, X., Qu, J., & Song, Y. (2020). RETRACTED ARTICLE: Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway. Stem Cell Research & Therapy, 11(1), 2. 
3. Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017). Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway. Scientific Reports, 7(1), 41085. 
4. Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014). Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism. PLoS ONE, 9(5), e97554. 
5. Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Furness, S. G., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2016). Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochemical Pharmacology, 118, 68–87. 
6. Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015). Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Scientific Reports, 5(1), 18039. h
7. Baris, E., Portakal, H. S., Aslan, A., Karagonlar, Z. F., & Tosun, M. (2025). Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages. Naunyn-Schmiedeberg S Archives of Pharmacology, 398(11), 16229–16239. 
8. Hart, N. J., Weber, C., Papas, K. K., Limesand, S. W., Vagner, J., & Lynch, R. M. (2018). Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion. American Journal of Physiology-Cell Physiology, 316(1), C48–C56.